Actively Recruiting
Safety Monitoring of MenQuadfi Meningococcal Vaccine in People Aged 6 Weeks to 55 Years in South Korea
Led by Sanofi · Updated on 2026-07-29
706
Participants Needed
9
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating the safety of MenQuadfi, a meningococcal vaccine for groups A, C, Y, and W conjugated with tetanus toxoid, when given to people aged 6 weeks to 55 years in real-world healthcare settings. The study focuses on monitoring adverse drug reactions, including those not fully recognized or unexpected in usual clinical practice. Participants receive MenQuadfi as part of routine healthcare vaccination on the day they join the study. This observational study does not administer treatments but observes the vaccines use according to approved local guidelines. Different age groups have varying monitoring periods after vaccination, from about 44 days to 13 months. During the study, participants will be observed for injection site and systemic reactions up to 7 days post-vaccination, any non-serious adverse events or drug reactions up to 30 days, and serious or special interest adverse events throughout the follow-up period. The study includes infants and adults, with safety monitored through clinical observation and data collection. Participation duration varies by age group, with follow-up extending up to 13 months for the youngest infants.
CONDITIONS
Brief Title
Post Marketing Surveillance Study for MenQuadfi® [Meningococcal (Groups A, C, Y, W) Polysaccharide Tetanus Toxoid Conjugate Vaccine] Administered in Participants Aged 6 Weeks to 55 Years in Republic of Korea
Research Team
T
Trial Transparency email recommended (Toll free for US & Canada)
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here